(Date:7/25/2008)... Management to discuss second quarter financial re.../ - Labopharm Inc. (TSX: DDS;,NASDAQ: DDSS) today ...riday, August 8 at 8:30 a.m. (ET) to discuss its s...ll report its second quarter 2008 financial,result...same day., To access the conference call by telep...
(Date:7/25/2008)...f certain cleaning products reduces lung function,... , FRIDAY, July 25 (HealthDay News) -- A clean, ...ealth, depending on what type of cleaning and air ...suggests that exposure to cleaning products or air...c compound (VOC) called 1,4 dicholorobenzene (1,4 ...
(Date:7/25/2008)...ALLAS, July 25 /PRNewswire/ -- BeaconEquity.com an... making news today., Investors can view all of th...//BeaconEquity.com/m , Today,s Trade Alerts inclu...ddleBrook Pharmaceuticals Inc. (Nasdaq: MBRK ), N... ADLR ), Affymetrix Inc. (Nasdaq: AFFX ) and,Abax...
(Date:7/25/2008)... - 180-Days of Marketing Exclusivity Beg...all/ -- Watson,Pharmaceuticals, Inc. (NYSE: WPI )...unced today that its subsidiary has commenced comm...Capsules USP product in the 40mg,strength from its...tion,with the launch, Watson has 180 days of marke...
Breaking Medicine News(10 mins):Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Health Hazards in Household Cleaners Exposed 2Health News:Health Hazards in Household Cleaners Exposed 3Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 2Health News:BeaconEquity.com Issues Technical Trade Alerts on Healthcare/Pharmaceutical Stocks: DUSA, MBRK, NOVA, ADLR, AFFX, ABAX 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2(Date:7/22/2008)... 22 /- Following a,thorough...f Progen,Pharmaceuticals Limited (ASX: PGL; Nasdaq...he PI-88 phase 3 study in liver cancer. Progen con...ting portfolio of compounds and,the company will a...pportunities through Merger & Acquisition activity...
(Date:7/22/2008)...peutics Development Initiative bring MJFF,s,curren...ine January 20,2009, NEW YORK, July 22 /PRNewswi...delivery of transformative treatments and a cure f...ion for Parkinson,s Research has awarded,$2.7 mill...s. The awards,were granted under MJFF,s Therapeuti...
(Date:7/22/2008)... Confirms Tyrima Exhibits Excellent Drug-Like ...lts Support Initiation of Phase II Clinical Trials...wire/ -- CeNeRx BioPharma,Inc., a clinical stage ...treatments for diseases of the central nervous sys...didate Tyrima(TM) into Phase II trials for the,tre...
(Date:7/22/2008)...f., July 22 /- Hyperion,Therapeutics,...t enrollment,in its Phase 1/2 clinical trial to ev...ging effects of HPN-100 (formally called GT4P) ver...s with urea cycle disorders,(UCD). The company pla...ter,of this year., (Logo: http://www.newscom.com...
Breaking Medicine Technology:Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 2Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 2CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 3CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study 4Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3Easy Does It Eases Holiday Stress 8766 1Easy Does It Eases Holiday Stress 8766 2Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis 8762 1Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis 8762 2Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis 8762 3Sinovac Reports Top Line Preliminary Phase II Results of Pandemic Influenza 28H5N1 29 Whole Viron Vaccine 2375 1Sinovac Reports Top Line Preliminary Phase II Results of Pandemic Influenza 28H5N1 29 Whole Viron Vaccine 2375 2Sinovac Reports Top Line Preliminary Phase II Results of Pandemic Influenza 28H5N1 29 Whole Viron Vaccine 2375 3Gold nanoparticle probes may allow earlier cancer detection 8756 1Gold nanoparticle probes may allow earlier cancer detection 8756 2Gold nanoparticle probes may allow earlier cancer detection 8756 3...nt Improvement in Psoriasis,Signs and Symptoms at ...Half Achieved 90 Percent Improvement, ABBOTT PARK,...Phase II study results show Abbott,s investigation...significantly in the majority,of patients treated....e to severe psoriasis achieved 75 percent improvem...
...4, 2007 - Lux Biosciences,Inc., a privately held ...ophthalmic diseases, announced today that the comp..., is the subject of two,presentations at the Assoc...RVO) annual meeting, being held May 6-10 in Fort,L...on being given on May 5 during a,satellite session...
Other Medicine Technology:Abbott's Investigational Treatment ABT-874 Shows Positive Results,in Phase II Psoriasis Study 2Abbott's Investigational Treatment ABT-874 Shows Positive Results,in Phase II Psoriasis Study 3Abbott's Investigational Treatment ABT-874 Shows Positive Results,in Phase II Psoriasis Study 4Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 2Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 3Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 4Rotating 360 degrees, 3 mm x 7 mm bite.
Right side cutting.
Backward cutting, 3 mm x 7 mm bite, length of shaft 100 mm, overall length 7 inches.
20 mm. Plastic, methylmethacrylate. Supplied sterile.
Medicine Products: